| # | Drug | Count |
|---|---|---|
| 0 | CARBOPLATIN | 16 |
| 1 | OLAPARIB | 16 |
| 2 | DOCETAXEL | 15 |
| 3 | DOCETAXEL ANHYDROUS | 15 |
| 4 | ENZALUTAMIDE | 15 |
| 5 | LEUPROLIDE ACETATE | 13 |
| 6 | PREDNISOLONE | 13 |
| 7 | PREDNISOLONE ORAL | 13 |
| 8 | PREDNISOLONE ORAL SOLUTION | 13 |
| 9 | LETROZOLE | 12 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | CABAZITAXEL | 11 | 0.0031 |
| 1 | VALERIAN | 1 | 0.0014 |
| 2 | OLAPARIB | 16 | 0.0007 |
| 3 | TALAZOPARIB | 1 | 0.0005 |
| 4 | GOSERELIN | 6 | 0.0004 |
| 5 | TRIPTORELIN PAMOATE | 1 | 0.0004 |
| 6 | ABIRATERONE ACETATE | 11 | 0.0003 |
| 7 | ENZALUTAMIDE | 15 | 0.0003 |
| 8 | LETROZOLE TABLETS | 12 | 0.0002 |
| 9 | DOCETAXEL ANHYDROUS | 15 | 0.0002 |
| # | Drug class | Count |
|---|---|---|
| 0 | Microtubule Inhibitor [EPC] | 24 |
| 1 | Corticosteroid [EPC] | 16 |
| 2 | Platinum-based Drug [EPC] | 16 |
| 3 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 16 |
| 4 | Androgen Receptor Inhibitor [EPC] | 15 |
| 5 | Aromatase Inhibitor [EPC] | 13 |
| 6 | Alkylating Drug [EPC] | 9 |
| 7 | Proton Pump Inhibitor [EPC] | 4 |
| 8 | RANK Ligand Inhibitor [EPC] | 4 |
| 9 | Kinase Inhibitor [EPC] | 3 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 16 | 0.0007 |
| 1 | Androgen Receptor Inhibitor [EPC] | 15 | 0.0002 |
| 2 | Microtubule Inhibitor [EPC] | 24 | 0.0001 |
| 3 | Aromatase Inhibitor [EPC] | 13 | 0.0001 |
| 4 | CD30-directed Immunoconjugate [EPC] | 1 | 0.0001 |
| 5 | Vasopressin V2 Receptor Antagonist [EPC] | 1 | 0.0001 |
| 6 | Platinum-based Drug [EPC] | 16 | 0.0001 |
| 7 | Estrogen Receptor Antagonist [EPC] | 2 | 0.0000 |
| 8 | Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] | 1 | 0.0000 |
| 9 | Human Immunoglobulin G [EPC] | 1 | 0.0000 |